Crossmark

Redefining therapeutics in vATTR: Evaluation of response predictors to tafamidis and patisiran treatment in a non-endemic area. A proposal for a novel individualised therapeutic approach

Crossref DOI link: https://doi.org/10.1016/j.nrl.2025.501920

Published Print: 2026-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Martínez-Vicente, L.

Gajate-García, V.

Gutiérrez-Gutiérrez, G.

Guerrero-Peral, Á.L.

Horga, A.

Guerrero-Sola, A.

Álvarez-Troncoso, J.

Restrepo-Córdoba, M.A.

Goirigolzarri-Artaza, J.

Martín-Albarrán, S.

Valverde-Megías, A.

González-López, E.

García-Pavía, P.

Matías-Guiu, J.

Galán-Dávila, L.
License Information

Text and Data Mining valid from 2026-04-01

Text and Data Mining valid from 2026-04-01

Version of Record valid from 2025-07-26
More Information

This article is maintained by: Elsevier

Article Title: Redefining therapeutics in vATTR: Evaluation of response predictors to tafamidis and patisiran treatment in a non-endemic area. A proposal for a novel individualised therapeutic approach

Journal Title: Neurología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.nrl.2025.501920

Content Type: article

Copyright: © 2025 Sociedad Española de Neurología. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below